PolyPid (PYPD) has released an update.
PolyPid Ltd. has announced the enrollment of the last patient needed for an unblinded interim analysis in its SHIELD II Phase 3 trial, which is evaluating the efficacy of D-PLEX100 in preventing surgical site infections after abdominal colorectal surgeries. The interim analysis is set to occur this quarter, with the potential to conclude the trial early if positive efficacy is shown. The company is on track for the full enrollment of 630 subjects and expects to announce top-line results in the first quarter of 2025.
For further insights into PYPD stock, check out TipRanks’ Stock Analysis page.
